(19)
(11) EP 2 843 405 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.10.2023 Bulletin 2023/40

(45) Mention of the grant of the patent:
23.08.2023 Bulletin 2023/34

(21) Application number: 14191378.0

(22) Date of filing: 04.02.2011
(51) International Patent Classification (IPC): 
G01N 33/487(2006.01)
(52) Cooperative Patent Classification (CPC):
G01N 33/48721; C12Q 1/6869
 
C-Sets:
C12Q 1/6869, C12Q 2523/305, C12Q 2563/116, C12Q 2565/631;

(54)

Systems and methods for manipulating a molecule in a nanopore

Systeme und Verfahren zur Manipulation eines Moleküls in einer Nanopore

Systèmes et procédés permettant de manipuler une molécule dans un nanopore

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 08.02.2010 US 658591
08.02.2010 US 658601
08.02.2010 US 658602
08.02.2010 US 658603
08.02.2010 US 658604

(43) Date of publication of application:
04.03.2015 Bulletin 2015/10

(62) Application number of the earlier application in accordance with Art. 76 EPC:
11740145.5 / 2534284

(73) Proprietor: Roche Sequencing Solutions, Inc.
Pleasanton, CA 94588 (US)

(72) Inventors:
  • Chen, Roger
    San Jose, CA 95138 (US)
  • Davis, Randy
    San Jose, CA 95138 (US)

(74) Representative: Gill, David Alan 
WP Thompson 138 Fetter Lane
London EC4A 1BT
London EC4A 1BT (GB)


(56) References cited: : 
EP-A1- 1 645 628
US-A1- 2005 127 035
 WO-A1-2008/124107
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).